Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model. (Q45962698)

18 December 2017

title

Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model. (English)

1 reference

18 December 2017

1 reference

1 reference

Ruifang Mi

1

1 reference

18 December 2017

Jianhui Ma

2

1 reference

18 December 2017

Dechang Zhang

3

1 reference

18 December 2017

Limin Li

4

1 reference

18 December 2017

Hongbing Zhang

5

1 reference

18 December 2017

publication date

1 June 2009

1 reference

18 December 2017

Journal of Genetics and Genomics

published in

1 reference

18 December 2017

volume

36

1 reference

18 December 2017

issue

6

1 reference

18 December 2017

page(s)

355-361

1 reference

18 December 2017

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

PI3K and mTOR inhibitors: a new generation of targeted anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

Do we have a cure for tuberous sclerosis complex?

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

The tuberous sclerosis complex

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

1 reference

7 January 2021

Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

Cotargeting survival signaling pathways in cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

AKT/PKB signaling: navigating downstream

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

Akt regulates growth by directly phosphorylating Tsc2

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR

1 reference

https://api.crossref.org/works/10.1016%2FS1673-8527%2808%2960124-1

7 January 2021

10.1016/S1673-8527(08)60124-1

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017